Filip Rázga, PhD., MPH

Head of Diagnostics Division
CEO, Co-founder

Experience: 20+ years
Specialization: Biotechnology, Oncology, Structural Biology, Public Health

Publon    Research Gate

Professional background

National Centre for Biomolecular Research (CZ)
Bowling Green State University (Ohio, USA)
Center of Molecular Biology and Gene Therapy (CZ)
Slovak Academy of Sciences (SVK)

Dr Razga has 20+ years of professional research experience in oncology with a biotechnology focus in the last decade. He is trained in Physical and Biomolecular chemistry with primary research interest in RNA structure and function. After working at the National Centre for Biomolecular Research (CZ) he became an associate at Bowling Green State University (Ohio, USA) and collaborated with Joachim Frank, the Nobel Prize laureate in Chemistry (2017) from Howard Hughes Medical Institute. Dr Razga then accepted a position at the Center of Molecular Biology and Gene therapy (CZ) as a specialist in molecular diagnostics. He later became a lab leader at the Slovak Academy of Sciences with a research focus in anticancer therapy. In parallel, he was the Research delegate of a $700k project dedicated to the development of therapy for type I diabetes founded by the leading global organization – Juvenile Diabetes Research Foundation (USA).

Awarded by the Ministry of Education, Youth and Sports of the Czech Republic

Dr Razga holds multiple awards including the Award of the Ministry of Education, Youth and Sports of the Czech Republic and the Award of the Slovak Academy of Sciences and had been the recipient of the prestigious international Marie Skłodowska-Curie Fellowship.

Scientific activities

Dr Razga has led several national and international projects with a total volume of €500k+ so far, addressing the problem of promiscuity of therapeutic oligonucleotides.

He is the author of 60+ scientific papers and developed several proprietary technologies aiming at precise diagnostics and personalized therapy approaches.

Selecta Biotech SE

Dr Razga co-founded Selecta Biotech in 2018 with the aim to translate these innovations into clinical practice to improve cancer diagnostics and help reduce the side-effects of current treatment regimens.

error: Content is protected !!